Laminin & Tf and 2C5 antibod. | AS oligonucleotide, experimental therapy | Fujita et al. (2007) J Control Release 122(3):356 |
Caspases 3 & 8 | AS oligonucleotide, experimental therapy | Gdynia et al. (2007) Mol Cancer Res 5(12):20 |
miR-21 | AS oligonucleotide, experimental therapy | Gabriely et al. (2008) Mol Cell Biol 28(17):536 |
miR-21 | AS oligonucleotide, experimental therapy | Shi et al. (2008) Zhonghua Yi 25(5):497 |
TGF-beta and immune activation | AS oligonucleotide (NPs), experimental therapy | Schneider et al. (2008) J Neuroimmun 195(1-2):21 |
TGF-beta and immune activation | AS oligonucleotide, experimental therapy | Vega et al. (2008) Future Oncol 4(3):433 |
Heat shock-protein 27 (Hsp27) | AS oligonucleotide, experimental therapy | Aloy et al. (2008) Int J Radiat Oncol Biol Phys 70(2):543 |
VEGF | AS vector, experimental therapy | Lin et al. (2008) Cancer Sci 99(12):2540 |
TGF-beta 2 | AS oligodeoxynucleotide, clinical trial | Schlingensiepen et al. (2008) Rec Res Cancer Res 177:137 |
IGF-I | AS vector, clinical trial | Trojan et al. (2009) JAC 1:1 |
TGF-beta 2 | AS oligodeoxynucleotide, clinical trial | Hau et al. (2009) Expert Rev Anticancer Ther 9(11):166 |
IGF BP2 | AS vector, experimental therapy | Moore et al. (2009) Proc Natl Acad Sci USA 106(39):16675 |
CD133/ | AS oligonucleotide, experimental therapy | Yao et al. (2009) Oncol Rep 22(4):781 prominin-1 |
EGFR | AS oligonucleotide, experimental therapy | Loew et al. Anticancrer Agents Med Chem 9(6):703 |
TGF-beta | AS oligodeoxynucleotide, clinical trial | Vallieres (2009) IDrugs 12(7):445 |
miR-21 | AS oligonucleotide, experimental therapy | Li et al. (2009) Brain Res 25(1286):13 |
miR221/222 | AS oligonucleotide, experimental therapy | Zhang et al. (2009) Int J Oncol 34(6):1653 |
IGF-I | AS vector, clinical trial | Trojan et al. (2010) Biomed & Pharmaother 64(8):57 |
miR-21 | AS oligonucleotide, experimental therapy | Zhou et al. (2010) Oncol Rep 24(1):195 |
c-Met | AS oligonucleotide, experimental therapy | Chu et al. (2010) Oncol Rep 24(1):189 |
AKT2 | AS oligonucleotide, experimental therapy | Zhang et al. (2010) Oncol Rep 24(1):65 |
EGFR | AS oligonucleotide, experimental therapy | Li et al. (2010) Oncol Rep 23(6):1585 |
PED/PEA-15 (ERK1/2-inter. protein) | AS oligonucleotide, experimental therapy | Botta et al. (2010) Hum Gene Ther 21(9):1067 |
miR-21 & 5FU | AS oligonucleotide, experimental therapy | Ren et al. (2010) J Biomater Sci Polym Ed 21(3):303 |
miR-21 | AS oligonucleotide, experimental therapy | Zhou et al. (2010) Lab Invest 90(2):144 |
EGFR | AS oligonucleotide, experimental therapy | Kang et al. (2010) J Biomed Mater Res A 93(2):585 |
Laminin-411 | AS oligodeoxynucleotide, clinical trial | Ding et al. (2010) Proc Natl Acad Sci USA 107(42):18143 |
TGF-beta & T cell therapy | AS oligodeoxynucleotide, clinical trial | Dietrich et al. (2010) Curr Opin Oncol 2010; 22(6):604 |
Telomerase & taxifen | AS oligonucleotide, experimental therapy | Wang et al. (2010) Mol Med Report 3(6):935 |
VEGF | AS vector, experimental therapy | Yang et al. (2011) J Neurooncol 103(1):33 |
IGF-I | AS vector, clinical trial | Trojan & Anthony (2011) Curr Signal Transd Ther 6(3):411 |
TGF-beta | AS oligodeoxynucleotide, clinical trial | Jashinsky et al. (2011) Curr Pharm Biotechnol 12(12):220 |
TGF-beta | AS oligodeoxynucleotide, clinical trial | Hau et al. (2011) Curr Pharm Biotechnol 12(12):2250 |
PrPc | AS oligonucleotide, experimental therapy | Barbieri et al. (2011) Autophagy 2011 Aug 1; 7(8). [Epub] |
miR-10b | AS oligonucleotide, experimental therapy | Sun et al. (2011) Brain Res 1389:9 |
uPAR | AS vector, experimental therapy | Raghu et al. (2011) Mol Cancer 10:130 |
microRNA-7 | AS oligonucleotide, experimental therapy | Lee et al. (2011) Radiother Oncol 101(1):171 |
miR-221/222 | AS oligonucleotide, experimental therapy | Hao et al. (2012) Oncol Rep 27(5):1504 |